Pathway for Softgel vs Tablet Comparison [Design Issues]

posted by Obinoscopy  – USA, 2018-05-15 21:04 (2144 d 19:49 ago) – Posting: # 18764
Views: 2,527

Dear bebac_fan,

❝ I think this would need to go through a NDA/505(b)(2) pathway rather than an ANDA.



I share the same view with you on this.

However I have a case where a BE study was conducted comparing Metronidazole tablet (Reference) with Metronidazole soft gel (test). Both were IR. Is this acceptable?

Regards,

Scopy

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
117 visitors (0 registered, 117 guests [including 7 identified bots]).
Forum time: 15:53 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5